RUSSOMANNO v. SUNOVION PHARMACEUTICALS

CourtDistrict Court, D. New Jersey
DecidedMay 18, 2020
Docket3:19-cv-05945
StatusUnknown

This text of RUSSOMANNO v. SUNOVION PHARMACEUTICALS (RUSSOMANNO v. SUNOVION PHARMACEUTICALS) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
RUSSOMANNO v. SUNOVION PHARMACEUTICALS, (D.N.J. 2020).

Opinion

*NOT FOR PUBLICATION*

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

: GINA RUSSOMANNO, : : Plaintiff, : Civil Action No. 19-5945 (FLW) v. : : OPINION SUNOVION PHARMACEUTICALS and IQVIA : INC., : : Defendants. : :

WOLFSON, Chief Judge:

Plaintiff Gina Russomanno (“Plaintiff”), proceeding pro se, brings this employment action against her former employer, Sunovion Pharmaceuticals Inc. (“Sunovion”), and IQVIA, Inc., (“IQVIA”), (cumulatively, “Defendants”). Pending before the Court are the following: (1) each Defendant’s separate Motion to dismiss Plaintiff’s Complaint, wherein Plaintiff alleges a claim for “wrongful termination, without real just cause, by Covenant of Good Faith (and fair dealing) Exception”; and (2) Plaintiff’s Motion for Reconsideration of a prior Court Order that denied her request for remand. For the reasons expressed herein, Defendants’ Motions to Dismiss are GRANTED, and Plaintiff’s Motion for reconsideration is DENIED. I. FACTUAL BACKGROUND AND PROCEDURAL HISTORY

The following facts are drawn from the Complaint and are assumed to be true for the purpose of this Motion.1 On August 15, 2016, Plaintiff received a formal written job offer from

1 I note that the Plaintiff attaches voluminous exhibits to the Complaint, including various signed agreements, that this Court can consider on a Motion to dismiss. Schmidt v. Skolas, 770 F.3d 241, 249 (3d Cir. 2014) (“To decide a motion to dismiss, courts generally consider only the Sunovion for a position as a Therapeutic Specialist (the “Letter Offer”). Complaint (“Compl.”), Ex. B. The Letter Offer, which Plaintiff signed and accepted on that same date, included information about compensation and training associated with the position of a Therapeutic Specialist. Id. In addition, the first page of the Letter Offer explained that Plaintiff would be hired on an at-will basis: “[p]lease note that neither this letter nor any other materials constitute a

contract of employment with Sunovion; your employment with Sunovion will be on an at-will basis.” Id. On August 24, 2016, Plaintiff signed an “Invention, Non-Disclosure, Restricted Activity and Personal Conduct Agreement” (the “NDA”). The NDA contained a non-compete clause, and various terms and provisions that Plaintiff was required to adhere to during the course of her tenure at Sunovion. Id. Moreover, the NDA reiterated Plaintiff’s at-will status under a section entitled “No Employment Contract”: “I understand that this Agreement, alone or in conjunction with any other document agreement whether written or oral, does not constitute a contract of employment and does not imply that [my] employment will continue for any period of time.” Id.

As a Therapeutic Specialist, Plaintiff conducted “customer engagement” telephone calls, and sold pharmaceutical products to consumers who resided in New Brunswick, New Jersey. Id., Ex. B. In performing these tasks, Plaintiff alleges that she was required to meet sales quotas each quarter, and Sunovion assessed her performance based on data that it received from IQVIA. Id. at I, 13. While she worked at Sunovion, Plaintiff alleges that she maintained “acceptable goal attainment percentages,” ranging from “80%” to “over 85%.” Id. at 2. Nevertheless, Plaintiff avers that her manager, Jenna Yackish (“Ms. Yackish”), placed her on a performance

allegations contained in the complaint, exhibits attached to the complaint and matters of public record.”). improvement plan (“PIP”) for failing to reach 100% of her quotas for eight consecutive quarters.2 Id. at 13. The PIP was implemented with a timeline that spanned from October 24, 2018 to January 8, 2019. Id., Ex., B. However, the plan’s first paragraph informed Plaintiff that, “[a]t any time either during or after the PIP’s conclusion . . . management may make a decision about your

continued employment, up to and including termination[.]” Id. Moreover, a similar warning was contained in the last section of the plan, under the heading “Consequences of Continued Non- Performance”: “[f]ailure to comply with the expectations [herein] and to sustain this performance . . . may result in further disciplinary action, up to and including termination. All employment at Sunovion is at will. Employees are subject to discharge at any time with or without cause or notice.” Id. While the PIP was in effect, Ms. Yackish held progress “updates” with Plaintiff once a week. Id. at 17. During their meetings, Plaintiff alleges that Ms. Yackish made the following statements which are characterized as “oral agreements” in the Complaint: “[w]e don’t want to

let you go”; “[w]e want you to succeed”; “I want you to succeed”; “[d]o you want this. If you do then I want this for you”; “[t]his is going to be your quarter, I can feel it”; “I want this for you”; “[t]he PIP can be extended”; “[t]he PIP doesn’t necessarily mean termination. It can always be extended if you still don’t make goal.” Id. Despite these encouraging remarks, however, according to Plaintiff, Ms. Yackish “shut[] [her] down” on “field rides” and “debat[ed] Plaintiff’s action[s] toward success.” Id. Thereafter, Plaintiff alleges that she was terminated

2 An Exhibit attached to the Complaint indicates that Plaintiff fell short of her sales goals, as she attained the following percentages during the first eight quarters of her tenure at Sunovion: 97.75%; 79.73%; 89.19%; 93.52%; 99.05%; 84.91%; 84.33%; 87.57%. See Compl., Ex. B. from Sunovion on January 4, 2019, before “the documented PIP end date” on January 9, 2019. Id. at 5. Prior to her termination, Plaintiff alleges that she raised a concern about the calculation of her sales quotas to Sunovion. Id. at 4, 16. In particular, according to Plaintiff, she informed Sunovion that her geographic market, i.e., New Brunswick is a “long-standing, unchanged”

region with a “conforming footprint,” unlike other cities in the tri-state area which, for example, had “undergone multiple realignment shifts in footprint” that “affect the formula settings for sales history, market potential, and volumes[.]” Id. at 4. For reasons that are unclear from the Complaint, Plaintiff alleges that these geographical differences had an impact on her performance. Id. at 4, 16. However, Plaintiff states that Sunovion investigated these alleged matters, and concluded that the quota calculations for her geographic market were, in fact, accurate. Separate and apart from Sunovion’s own alleged miscalculations, Plaintiff alleges that it received inaccurate statistical data from IQVIA that impacted Sunovion’s assessment of her job

performance. Id. at II-IV. In particular, Plaintiff alleges that on January 4, 2019, Sunovion held a conference call with its “salesforce” to explain that IQVIA had furnished inaccurate data to Sunovion during the prior two years. Id. at II, 6. However, rather than discuss these alleged issues with her, Plaintiff alleges that Sunovion placed her on a PIP with the intention of terminating her, “to avoid . . . addressing how IQVIA[’s] negligent reporting and other Sunovion miscalculations” impacted her performance in her assigned market of New Brunswick. Id. at III- IV, 3. On January 11, 2019, Plaintiff filed a Complaint in the Superior Court of New Jersey, Law Division, Monmouth County, asserting a claim for “wrongful termination, without real just cause, by Covenant of Food Faith (and fair dealing) Exception,” against Sunovion and IQVIA. On February 15, 2019, Defendants removed that case to this Court, on the basis of diversity jurisdiction pursuant to 28 U.S.C. § 1441(a). On February 22, 2019, Plaintiff filed a motion to remand that this Court denied, finding that Defendants’ removal of this action was proper.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hertz Corp. v. Friend
559 U.S. 77 (Supreme Court, 2010)
Owen Equipment & Erection Co. v. Kroger
437 U.S. 365 (Supreme Court, 1978)
United States v. Bestfoods
524 U.S. 51 (Supreme Court, 1998)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Blystone v. Horn
664 F.3d 397 (Third Circuit, 2011)
Phillips v. County of Allegheny
515 F.3d 224 (Third Circuit, 2008)
Huber v. Taylor
532 F.3d 237 (Third Circuit, 2008)
Bell v. KA Industrial Services, LLC
567 F. Supp. 2d 701 (D. New Jersey, 2008)
Fowler v. UPMC SHADYSIDE
578 F.3d 203 (Third Circuit, 2009)
English v. College of Medicine and Dentistry of NJ
372 A.2d 295 (Supreme Court of New Jersey, 1977)
Florham Park Chevron, Inc. v. Chevron U.S.A., Inc.
680 F. Supp. 159 (D. New Jersey, 1988)
Noye v. Hoffmann-La Roche Inc.
570 A.2d 12 (New Jersey Superior Court App Division, 1990)

Cite This Page — Counsel Stack

Bluebook (online)
RUSSOMANNO v. SUNOVION PHARMACEUTICALS, Counsel Stack Legal Research, https://law.counselstack.com/opinion/russomanno-v-sunovion-pharmaceuticals-njd-2020.